BioStem Technologies will participate in the Symposium on Advanced Wound Care Spring meeting in Charlotte, NC, from April 8-12, 2026. The company announced it will highlight its recently introduced Neox Product line, which expands its capabilities across multiple tissue formats and provides physicians with differentiated options based on clinical needs, handling preferences, and site of care requirements. According to Chairman and CEO Jason Matuszewski, this addition reinforces the company's focus on advancing science and equipping clinicians with data and tools to improve patient outcomes.
The expanded portfolio offers what the company describes as the most comprehensive suite of placental and umbilical cord tissue solutions, backed extensively by both randomized clinical trials and real-world evidence. BioStem's participation in SAWC demonstrates its continued investment in clinical research and medical education as it works to expand access to advanced healing technologies across various care settings. The company's quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks and comply with current Good Tissue Practices and current Good Manufacturing Processes.
In addition to booth presentations during exhibit hours, BioStem is hosting a lunch symposium titled "A New Season in Wound Care: An Expanded Portfolio Grounded in Evidence" on Thursday, April 9th, from 12:15 p.m. to 1:45 p.m. in Room 207C. The session will feature presentations by Dr. Wendy Weston, PhD, CTBS, William Marston, MD, and Herbert Slade, MD, and will include discussion of several key topics. These include an introduction to the newly expanded product portfolio, the science behind its innovative suite of birth tissue products, recently published results of a randomized controlled trial on diabetic foot ulcers, and practical guidance on incorporating these therapies into clinical practice.
BioStem will also present a new scientific poster presentation available for viewing in Exhibit Hall 1C under poster number LR-020. The company leverages proprietary processing technologies including BioRetain, CryoTek and SteriTek, designed to optimize preservation of natural tissue properties for clinical use. The company's portfolio of quality brands includes its Neox, Clarix, VENDAJE and American Amnion product lines. More information about the company is available at https://www.biostemtechnologies.com, and the latest news and updates relating to the company are available at https://tinyurl.com/bsemnewsroom.
For business and technology leaders in the healthcare sector, BioStem's presentation at SAWC represents significant developments in regenerative medicine commercialization. The company's emphasis on both randomized clinical trials and real-world evidence addresses growing demands for data-driven medical solutions, while its expanded tissue format capabilities could influence treatment protocols across wound care specialties. The integration of the Neox product line into BioStem's existing portfolio suggests consolidation trends within the regenerative medicine market, potentially affecting competitive dynamics and investment patterns in biomedical innovation.
The focus on diabetic foot ulcer treatments highlights addressing a growing global health concern with advanced tissue technologies, while the company's compliance with AATB standards and cGMP/cGTP regulations demonstrates the maturation of regulatory frameworks for perinatal tissue products. These developments have implications for healthcare providers seeking evidence-based solutions, investors evaluating growth opportunities in regenerative medicine, and policymakers considering regulatory approaches to advanced tissue therapies. The symposium presentations will provide insights into how clinical evidence is being translated into practical treatment options across care settings.
